Released Aug 11, 2025, before the open
10-Q filed Aug 11, 2025, 42 days after period end · 0001171843-25-005261
Q2 2025 · 10-Q
Revenue$0.00$0.00 −100.0% vs Q2 2024no prior Q1 2025 on file
Net Income-$19.88M-$19.88M N/M vs Q2 2024N/M vs Q1 2025
EPS, diluted—
Operating Income-$21,066,000N/M
Operating Cash Flowderived-$11,832,000N/M
Free Cash Flowderived-$11,832,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $0.00 | $850.00K | $0.00 | — |
| Net Income | -$19.88M | -$13.08M | -$11.28M | -$8.49M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR